Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. - Test2 - elhamkhani - TriplyDB

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

http://www.wikidata.org/entity/Q38256360

about

Amyloidosis in Retinal Neurodegenerative Diseases Amyloid-β Receptors: The Good, the Bad, and the Prion Protein PET Imaging of Epigenetic Influences on Alzheimer's Disease Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date Diabetes mellitus and cognitive impairments Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's Disease.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer's Disease Model Mice Targeting Beta-Amyloid Production.Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2-Related Inflammatory Response.β-Amyloid peptides and amyloid plaques in Alzheimer's disease.Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.Study of Exosomes Shed New Light on Physiology of Amyloidogenesis.New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.Sex Hormone Decline and Amyloid β Synthesis, Transport and Clearance in the Brain.Hypoxia Affects Neprilysin Expression Through Caspase Activation and an APP Intracellular Domain-dependent Mechanism.The Degradome database: expanding roles of mammalian proteases in life and disease.Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta.Editorial on, "Amyloid-beta clearance in Alzheimer's disease".Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.Neuroinflammatory responses in Alzheimer's disease.Alzheimer's disease and modern lifestyle: what is the role of stress?Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

P2860

Q26739839-E847C5A4-0A42-4EDA-87F3-994E417D7BF3 Q26771532-9B262321-EEE4-40F9-B0DF-77D6607CE153 Q26776178-A534DC72-8A88-4689-A8FE-63D9AA31EB58 Q27027707-D2872C07-EC36-4E47-9AF8-07BE835135B1 Q28070064-A74CC54F-DE8E-4933-B016-68B0FCF0FC8C Q28079459-6629BFBA-2F9F-4A48-9B3C-1DAA577042B5 Q36036376-C07A612F-C3B7-477B-8905-AB2DD3FF39D8 Q37595978-47053E85-3375-4742-95AE-752A71776C43 Q37685356-7237F554-9DA4-4B5F-B5E4-F2B988C99744 Q37714716-D0F490CC-8884-492C-BA15-BA9EB5B020B7 Q38265124-DB07D725-8857-4ACC-8ECC-4106BC7AA822 Q38685645-82EDDDF9-A250-44F0-A45A-5B2269D36AFF Q38777380-2991E0E9-54C7-49B4-9E7B-711BE7CF1D9E Q38834930-4A1395AA-3730-4C35-9118-2B41124F40D0 Q38955319-11B89C77-470D-4DF7-B62F-C852AAF28C07 Q40263247-498C0DAB-B850-41BE-9E75-7D5C50CB35F2 Q40338688-292C218C-FCFF-4EC2-AA67-D362BDA1C3B0 Q41190059-74639BB2-13A3-43BC-84A3-135002723E4A Q41549636-4C4439E4-D72E-4E34-81B7-6CE889F6CA78 Q42621653-E4E7355F-C720-426D-A578-03D0F93006DC Q43015317-6D8E07C2-DB55-4F4D-94CE-4D26CD8463AA Q47195553-3FC50989-D760-4FAC-8646-1115A645D621 Q47259208-1300C222-1A16-42AE-9628-B53C03C22201 Q53366494-6904252B-A283-41C2-8290-F26E8B1115BC Q58804503-C4BCF594-366F-4117-B90F-C79B15103CE1

P2860

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

http://www.wikidata.org/entity/Q38256360

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Amyloid-clearing proteins and ...... target in Alzheimer's disease.

@en

type

label

Amyloid-clearing proteins and ...... target in Alzheimer's disease.

@en

prefLabel

Amyloid-clearing proteins and ...... target in Alzheimer's disease.

@en

P1433

Q38256360-434983CF-CC59-44FB-BE4E-3BF7E7849B77

P1476

Q38256360-B8F60976-B005-40A7-80F5-9AAC27CE0CC6

P2093

Q38256360-581460A7-FF3D-47D5-A14C-E8C98CA77EF4

Q38256360-8D2CA3A2-4D49-46D2-874C-3CE1B204DC8B

Q38256360-F2F471C6-87B6-4272-9F94-618CE828F64B

Q38256360-F448D8A2-A269-491D-8DDD-AC5C7F230D67

P2860

Q38256360-01810FEA-4634-4522-A887-54BB863F272A

Q38256360-0364283D-72EC-41B1-96F2-B0CDE72033E6

Q38256360-03DBA8B8-5A0D-4688-8295-C9DF23C411B7

Q38256360-053647EE-070E-49D9-B8B4-40387B482F60

Q38256360-066844B0-78AE-4DBF-9655-783877837B4C

Q38256360-08DEA29B-EEE2-4D9A-99CC-5D0597A75392

Q38256360-0B3B7F60-5643-48F9-A6C6-FEA113EA57E5

Q38256360-0C7E3061-3062-400D-8131-18E8B509716A

Q38256360-0E8B0E97-01B0-4DA9-BF24-943929C29F86

Q38256360-0EBBDA5F-1366-41B6-A4D7-5BD08F76336C

P304

Q38256360-61C9FA43-9B3A-4159-A5B4-6EE1F336A69F

P31

Q38256360-0977740d-d10e-4deb-bafa-2974b180cbad

Q38256360-FB2C6506-4713-408C-B61E-038ABB037B2B

P356

Q38256360-BC1C376B-111E-46C0-AB50-6CA3A0CED281

P478

Q38256360-871EDCA7-08A5-47F3-BD35-E47341A8BF81

P577

Q38256360-BD897D0F-A585-4D47-AE68-4844E82CD252

P5875

Q38256360-7F575000-CAE5-434C-A0A8-AD9D3F71D47D

P698

Q38256360-C0739033-6BFC-41A2-81AD-1BE4E4BFBF6A

P921

Q38256360-EFE64B4E-687A-4C26-B5C9-BB2605D6A69D

P932

Q38256360-C43E7008-7469-4D16-BD76-3E93BEE941E7

P356

FNAGI.2014.00235

P1433

Frontiers in Aging Neuroscience

P1476

Amyloid-clearing proteins and ...... target in Alzheimer's disease.

@en

P2093

Anthony J Turner

http://www.w3.org/2001/XMLSchema#string

Caroline Kerridge

http://www.w3.org/2001/XMLSchema#string

Natalia N Nalivaeva

http://www.w3.org/2001/XMLSchema#string

Nikolai D Belyaev

http://www.w3.org/2001/XMLSchema#string

P2860

The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?

Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria

Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE

Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling

Impact of apolipoprotein E on Alzheimer's disease

The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele

Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease

Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease

P304

235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FNAGI.2014.00235

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266401435

http://www.w3.org/2001/XMLSchema#string

P698

25278875

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4166351

http://www.w3.org/2001/XMLSchema#string